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Available online 29 June 2016Objectives: The physiological role of the contact system remains inconclusive. No obvious clinical complica-
tions have been observed for factor XII (FXII), prekallikrein (PK), or highmolecularweight kininogendeﬁciencies
even though the contact system in vitro is associated with coagulation, ﬁbrinolysis, and inﬂammation. A global
generation assay measuring the initial phase of the contact system could be a valuable tool for studies of its
physiological role.
Design andmethods:We investigatedwhether such amethod could be developed using the principle of the
Calibrated Automated Thrombin generation method as a template.
Results: A suitable kallikrein speciﬁc ﬂuorogenic substrate was identiﬁed (KM = 0.91 mM, kcat = 19 s−1),
and kallikrein generation could bemeasured in undiluted plasma when silica was added as activator. Disturbing
effects, including substrate depletion and the inner-ﬁlter effect, however, affected the signal. These problems
were corrected for by external calibration with α2-macroglobulin-kallikrein complexes. Selectivity studies of
the substrate, experiments with FXII and PK depleted plasmas, and plasma with high or low complement
C1-esterase inhibitor activity indicated that the obtained and calibrated signal predominantly was related to
FXII-dependent kallikrein activity.
Conclusions: The ﬁndings described show that establishment of a kallikrein generation method is possible.
Potentially, this setup could be used for clinical studies of the contact system.
© 2016 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Coagulation factor XII
Kallikreins
Methods
Enzymes
Enzyme activators1. Introduction
Four plasma proteins comprise the contact activation system [1].
In plasma, prekallikrein (PK) and factor XI (FXI) are mostly found in
complex with the non-enzymatic co-factor high molecular weight
kininogen (HMWK) [2,3]. Factor XII (FXII), on the other hand, circulates
unbound. The contact system is initiated when encountered with acti-
vating surfaces. While the exact mechanism is unknown, the surface
causes a conformational change in FXII rendering it susceptible forWK, high molecular weight
C1-inhibitor, complement C1-
od, the calibrated automated
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ty of Clinical Chemists. Publishedcleavage [4]. Once cleaved, activated FXII (FXIIa) can activate neighbor-
ing PK and FXI bound to the surface through HMWK. Ampliﬁcation of
the system follows from the ability of kallikrein to generate FXIIa [5].
Several protease inhibitors regulate the contact system. Complement
C1-esterase inhibitor (C1-inhibitor) is predominating [6], but contribu-
tions from α2-macroglobulin (α2M) and other inhibitors have been
observed [7,8]. In vitro experiments reveal connections between the
contact system and coagulation, ﬁbrinolysis, and inﬂammation. FXI
serves as the link between contact activation and coagulation as its
activation initiates the intrinsic pathway of coagulation and the forma-
tion of thrombin [9]. In vivo, FXII, PK, andHMWKdeﬁciencies are not as-
sociated with bleeding tendencies, questioning the role of the contact
system in normal haemostasis [1]. Recent studies, however, have
shown that FXII deﬁcient mice are protected from occlusive thrombi
in experimental thrombosis models [10]. Other studies suggest inhibi-
tion of FXII and FXI as alternative anti-coagulant approaches [11].
Decreased or absent C1-inhibitor activity is associated with symptoms
that are mainly related to activation of inﬂammation [1].
A sensitive global activity assay measuring contact activation is cur-
rently not available, and in general, there is only a limited assortment of
biomarker assays available to measure the contact system [12–17].
Studies of the connection between the contact system and clinicalby Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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that measures the contact system may, potentially, facilitate such
investigations.
The Calibrated Automated Thrombin generation method (CAT-
method) is a global generation test that utilizes a ﬂuorogenic substrate
to measure the thrombin generation potential in human plasma
after initiation of the extrinsic pathway of coagulation [18]. The CAT-
method has proven to be a valuable tool to study disturbances of the
coagulation system in vitro, and it shows potential for routine clinical
application [19]. The use of a synthetic ﬂuorogenic substrate tomeasure
thrombin generation in undiluted plasma is, however, associated with
several complications such as substrate depletion, the inner-ﬁlter effect,
and cleavage of substrate by α2M-thrombin [20]. In the CAT-method,
these complications have been circumvented by unique approaches
developed by Hemker and colleagues [18,21]. We investigated if the
CAT-method could be used as a template for a method to measure
contact activation through kallikrein generation after initiation of the
contact system.
2. Materials and methods
2.1. Buffers
“BSA60 buffer” (20 mM Hepes, 0.02% NaN3, 60 g/L bovine serum
albumin (BSA), pH = 7.4). “BSA5 buffer” (20 mM Hepes, 0.02% NaN3,
5 g/L BSA, pH = 7.4). “BSA-blank buffer” (20 mM Hepes, 150 mM
NaCl, 0.02% NaN3, pH = 7.4). “Gel ﬁltration buffer” (20 mM Hepes,
300 mM NaCl, 0.02% NaN3, pH = 7.4). “SDS sample buffer”
(2× Laemmli Sample Buffer (Bio-Rad, Hercules, California, U.S.)).
“PBS-TW buffer” (Phosphate-buffered-saline (PBS), 0.05% Tween-20,
pH = 7.4).
2.2. Plasma
Sodium citrate (0.109 M) and ethylenediaminetetraacetic acid
(EDTA) stabilized plasma pools were obtained from 12 healthy
individuals, who did not take hormone supplements. Plasmawas frozen
at −80 °C in 300 μL ampoules. FXII depleted plasma (FXII DEP) was
obtained from Haematologic Technologies Inc. (HTI, Essex Junction,
Vermont, USA). Prekallikrein depleted plasma (PK DEP) was obtained
from Afﬁnity Biologicals (Ancaster, Ontario, Canada). EDTA stabilized
plasma was obtained from two hereditary angioedema (HAE) patients.
2.3. Reagents and materials
Corn trypsin inhibitor (CTI), 2 mg/mL, was obtained from HTI.
Soybean trypsin inhibitor (SBTI) was obtained from Sigma-Aldrich
Denmark ApS (Sigma, Brøndby, Denmark). Twenty-ﬁve milligram of
lyophilized SBTI was dissolved in 5 mL distilled water. Human comple-
ment C1-esterase inhibitor (C1-inhibitor) was obtained from CSL
Behring (Lyngby, Denmark), dissolved in 10 mL H2O, and dialyzed
towards 5 L PBS at 4 °C for 72 h in a Spectra/Por® Dialysis Membrane
molecular weight cut-off (MWCO) 6–8000 (Spectrumlabs®, Rancho
Dominquez, Ca, U.S.).
Afﬁnity puriﬁed kallikrein and FXIIa from human plasma were
obtained from Enzyme Research Laboratories (Swansea, UK). One
milligram of lyophilized protein was dissolved in 1 mL distilled water.
Plasmin from human plasma was obtained from Sigma. One milligram
was dissolved in 1 mL of distilled water containing 50% glycerol.
Human FXIa, 2.0 mg/mL in 50% glycerol, and human α-thrombin,
7.8 mg/mL in 50% glycerol, were obtained from HTI. BSA was from
Sigma.
Kallikrein sensitive chromogenic substrate, S-2302, was obtained
from Chromogenix (Mölndal, Sweden). Twenty-ﬁve milligram of
substrate was dissolved to a concentration of 4 mM in distilled
water. Fluorogenic substrate, OmniCathepsin ﬂuorogenic substrate(Cbz-Phe-Arg-AMC), was obtained from Enzo Life Science (Exeter, UK).
Fluorogenic substrate, Cbz-Pro-Phe-Arg-AMC, was synthesized on
request by Chempeptide Limited (Shanghai, China). Fluorogenic sub-
strate, Boc-Leu-Lys-Arg-AMC, was obtained from Bachem (Bubendorf,
Switzerland). All ﬂuorogenic substrateswere dissolved in DMSO to a con-
centration of 50 mM (stock solutions).
PK-11 and PK-32: in-house produced mousemonoclonal antibodies
against the heavy-chain of human prekallikrein/kallikrein. Nonsense
antibody: mouse anti-human osteoclast-associated receptor (OSCAR)
antibody [22].
APTT reagent, STA®-PTT Automate 5, was obtained from Triolab A/S
(Brøndby, Denmark). The powder was dissolved in 5 mL BSA60 buffer
(stock solution). Dextran sulfate sodium salt, with a molecular weight
of 500 kDa, was obtained from Pharmacia AB (Uppsala, Sweden).
Stock solution of dextran sulfate was prepared by dissolving 2 g of
dextran sulfate in 1 L of distilled water. Colloidal silica LUDOX AS-40,
a 40% (w/v) silica suspension in H2O, was obtained from Sigma (stock
solution). Polyethylene glycol with an average molecular weight of
6000 Da (PEG-6000) was obtained from Sigma.
Hiprep 16/60 Sephacryl S-200 HR column (Sephacryl column) was
obtained from GE Healthcare Europe GmbH (GE Healthcare, Brøndby,
Denmark). Vivaspin 20™, 100 kDa MWCO, sample concentrator
(Vivaspin sample concentrator) was obtained from GE Healthcare.
Immulon 2HB round-bottom 96-well plate (2HB plate) was obtained
from Thermo Scientiﬁc (Rochester, NY, U.S.). Fluoroskan Ascent™
Microplate Fluorometer (ﬂuorometer) was obtained from Thermo
Scientiﬁc. Thrombinoscope™ software was obtained from
Thrombinoscope BV (Maastricht, Netherlands).
2.4. Fluorogenic substrates
The kinetic constants were determined essentially as described
elsewhere [23]. The ﬂuorogenic substrate Boc-Leu-Lys-Arg-AMC was
diluted from stock solution in BSA60 buffer to obtain a ﬁnal concentra-
tion of 1000, 800, 600, 400, 200, 100, 50, or 0 μM in the well. For
Cbz-Pro-Phe-Arg-AMC and Cbz-Phe-Arg-AMC, the ﬁnal substrate
concentration was 2000, 1800, 1400, 1000, 800, 600, 400, or 0 μM in
thewell. The enzyme to be investigatedwas diluted from stock solution
in BSA5 buffer. The ﬁnal concentrations were 5.8 nM (kallikrein),
125 nM (FXIIa), 60.25 nM (plasmin), 272.5 nM (thrombin), or
3.125 nM (FXIa) in the well. α2M-kallikrein was diluted 1:4 in BSA5
and added to the plate (ﬁnal dilution of 1:24 in the well). The kinetic
parameters were determined using the following setup; 100 μL of
ﬂuorogenic substrate was added to a 2HB plate and the plate was
warmed for 5min, at 37 °C, in the ﬂuorometer. Twenty μL of enzyme so-
lution (preheated to 37 °C) was then added using the ﬂuorometer dis-
penser just before measurements were started. Each substrate
concentration was run in quadruple and hydrolysis was followed for
40 min. Michaelis-Menten curves were ﬁtted to the obtained data. kcat
was calculated from the determined Vmax, by ﬁrst converting the ﬂuo-
rescence units per time to concentration per time, using a calibration
curve, and then dividing this rate by the enzyme concentration.
2.5. Calibrator
2.5.1. Preparation of α2M-kallikrein complexes
Humanα2Mwas obtained using a slightmodiﬁcation of a procedure
described elsewhere [18,24]: To 1 vol of human plasma, 0.28 vol PEG-
6000 (25% in H2O) was added and the mixture was incubated for
30 min. After centrifugation (3000g), the precipitate was discarded
and the supernatant was mixed with an additional 0.72 vol PEG-6000
(25% in H2O). After 30 min incubation, the mixture was centrifuged
(3000g) and the precipitate was dissolved in 0.1 vol BSA-blank buffer
(“crude α2M”). To prepare α2M-kallikrein complexes, crude α2M was
diluted 1:8 in BSA-blank buffer and 100 μg/mL of kallikrein (ﬁnal
concentration) was added. The mixture was incubated overnight (ON)
Table 1
Investigation of kallikrein ﬂuorogenic substrates.
The kinetic constants of human kallikrein towards three ﬂuorogenic substrates.
Peptide sequence KM (mM) kcat (s−1) kcat/KM (M−1 s−1)
Cbz-Phe-Arg-AMC 0.83 (0.68–1.1) 33 (31–37) 4.0 · 104
Cbz-Pro-Phe-Arg-AMC 1.4 (0.99–1.5) 45 (39–47) 3.2 · 104
Boc-Leu-Lys-Arg-AMC 0.91 (0.84–0.96) 19 (18–20) 2.1 · 104
The results are presented asmedian and range of quadruple determinations performed in
buffer with high albumin concentration.
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Sephacryl column equilibrated with gel ﬁltration buffer. The fractions
containing α2M-kallikrein were pooled, concentrated, using Vivaspin
sample concentrators, and diluted in BSA5 buffer. The kallikrein-like
activity of the calibrator was adjusted to 200 nM, using chromogenic
substrate S-2302, and C1-inhibitor (200 μg/mL, ﬁnal concentration),
SBTI (150 μg/mL, ﬁnal concentration), and CTI (120 μg/mL, ﬁnal concen-
tration) were added to prevent kallikrein generation in the calibrator
sample when used in the method.
2.5.2. Western blot analysis
Samples of kallikrein (100 μg/mL), crude α2M (1:8), a mixture of
crude α2M (1:8) and kallikrein (100 μg/mL), as well as the pooled and
concentrated fractions from gel ﬁltration were diluted 1:10 in PBS-TW
buffer and subsequently 1:2 in SDS sample buffer. All samples were
heated for 8 min at 96 °C to denature proteins. The samples were sepa-
rated by SDS-PAGE with a 4–15% MiniPROTEAN® TGX™ precast gel
(Bio-Rad) using SDS running buffer (Bio-Rad), as described by the
manufacturer, for 60 min at 150 V. The proteins were transferred to a
polyvinylidene ﬂuoride membrane with a Trans-Blot® Transfer Pack
(Bio-Rad) using the Trans-Blot® Turbo™ Blotting System (Bio-Rad).
Themembranewas afterwards blocked for 30min,with PBS-TWbuffer,
and incubated ON at 4 °Cwith PK-11 (diluted to a ﬁnal concentration of
0.66 μg/mL in PBS-TW buffer). Next, the membrane was washed
three times with PBS-TW buffer and incubated for 1 h with horseradish
peroxidase conjugated rabbit anti-mouse IgG antibody (Zymax™,
Invitrogen) diluted 1:4000 (v/v) in PBS-TW buffer. Proteins were
visualized using 0.4 mg/mL of 3-amino-9-ethylcarbazole in 50 mM
acetate buffer (pH = 5.0) with 0.015% H2O2.
2.5.3. Stability of α2M-kallikrein complexes
200 μL ofα2M-kallikrein was added to 800 μL of citrate plasma pool.
The mixture was placed in a water bath (37 °C). At times zero, 30 min,
and 60 min, a sample of 100 μL was withdrawn and added to a 2HB
plate. The plate was warmed for 5 min in the ﬂuorometer. Immediately
before measurements were initiated, Boc-Leu-Lys-Arg-AMC was added
to pre-warmed BSA60 buffer and 20 μL of the solution was added to the
wells. The ﬁnal substrate concentration was 0.42 mM. The ﬂuorescence
development of the samples was recorded every 12 s, and the initial
velocity of the ﬁrst 3 min was calculated. For each time point, the initial
velocity was determined as the mean of three repetitions.
2.6. Activating reagent
The activators under study were tested in the following setup: 20 μL
of BSA5 together with 80 μL of citrate pool were added to a 2HB plateTable 2
Selectivity study of substrate Boc-Leu-Lys-Arg-AMC.
Kinetic constants of human kallikrein, FXIIa, FXIa, thrombin, and plasmin towards Boc-Leu-Lys
Kallikrein Factor XIIa
KM (mM) 0.91 (0.84–0.96) 0.92 (0.81–1.0)
kcat (s−1) 19 (18–20) 0.03 (ND)
kcat/KM (M−1 s−1) 2.1 · 104 33
The results are presented as median and range of quadruple determinations performed in buffand the plate was warmed in the ﬂuorometer to 37 °C. A start reagent
for each activator was prepared by diluting the stock solutions of the
activators in BSA60 buffer; Dextran sulfate was diluted to 600 μg/mL
and silica to 6mg/mL. The APTT reagentwas not diluted. Lower concen-
trations of the activators were prepared by further dilutions in BSA60.
Finally, the ﬂuorogenic substrate was added to each reagent at a con-
centration of 2.5 mM. Twenty microliter of the solutions were then
added to the plate and ﬂuorescence was measured every 12 s for
20min. Each activator concentrationwas run in duplicate. Theﬁnal con-
centrations of the activators in the well were; dilutions 1:6, 1:12, 1:18,
and 1:24 for the APTT reagent, 100, 50, 25, and 12.5 μg/mL for dextran
sulfate, and 1, 0.5, 0.25, 0.125, or 0 mg/mL for silica.
2.7. Calculations
The raw data obtained from a generation experiment in a citrate
pool (obtained as described in Section 2.8) were transferred to a
Microsoft Excel spreadsheet. The corrected calibrator curve was found
from a 6th-degree polynomial ﬁt of the recorded calibrator data. The
relation between the corrected andmeasured calibrator curves was cal-
culated [18] and used to convert the obtained ﬂuorescence units of the
generation sample into corrected ﬂuorescence units. The contribution
from α2M-kallikrein was subtracted as described previously [25]. The
ﬂuorescence units of the corrected generation curve were converted
to enzyme concentration by comparing them to the calibrator initial ve-
locity. The calculations were also conducted using the Thrombinoscope
software for comparison.
2.8. Validation of kallikrein generation
Calibrated kallikrein generation was determined using four wells
for each plasma sample tested. Two wells were used to determine
kallikrein generation (generationwells) and twowells were used for cal-
ibration of signal (calibrator wells). To generation wells, 20 μL of BSA5
buffer containing either 90 μg/mL of PK-32, 90 μg/mL of nonsense anti-
body, 480 μg/mL of C1-inhibitor, or buffer alone was added. To calibrator
wells, 20 μL of α2M-kallikrein, with an activity corresponding to 200 nM
kallikrein, was added. Next, 80 μL of the plasma samples to be tested
were added to thewells and theplatewaswarmed to37 °C. The following
plasmas were tested: Citrate pool, FXII DEP, PK DEP, HAE plasma, and
mixtures of the citrate pool and FXII DEP consisting of 50%, 75%, and
90% FXII DEP. Immediately before initiation of experiment, colloidal silica
and Boc-Leu-Lys-Arg-AMC were added to BSA60 buffer preheated to
37 °C. Twenty microliter of the solution was added to the wells. The
ﬁnal concentrations of silica and substrate were 0.24 mg/mL and
0.42 mM, respectively. Fluorescence was measured every 12 s for
25 min and calculations were conducted using the Thrombinoscope
software.
3. Results
3.1. Fluorogenic substrate
The Michaelis-Menten kinetics of three ﬂuorogenic substrates
for kallikrein [26] were determined in BSA60 buffer and the results
are listed in Table 1. Boc-Leu-Lys-Arg-AMC displayed lower kcat-Arg-AMC are shown.
Factor XIa Thrombin Plasmin
3.4 (3.3–3.4) 0.74 (0.62–0.89) 3.8 (3.5–4.0)
28 (28–29) 0.02 (ND) 3.7 (3.4–3.8)
8.2 · 103 27 974
er with high albumin concentration. ND: not determined.
Fig. 1.Westernblot analysis ofα2M-kallikrein complex (calibrator) preparation. The samples
include M: Molecular marker (Precision Plus ProteinTM KaleidoscopeTM Standards, Bio-Rad)
1: Kallikrein (5 μg/mL, ﬁnal concentration), 2: “Crude α2M” (1:160, ﬁnal concentration), 3:
“Crude α2M” incubated with kallikrein (1:160, ﬁnal concentration), and 4: Pooled fractions
from gel ﬁltration (1:160, ﬁnal concentration). The western blot was visualized using PK-11.
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Cbz-Pro-Phe-Arg-AMC (45 s−1). Cbz-Pro-Phe-Arg-AMC displayed the
lowest binding afﬁnity with an apparent KM value of 1.4 mM whereasFig. 2. Generation of signal in a citrate pool by different activating reagents. A: APTT reagent, ST
concentration of 100, 50, 25, and 12.5 μg/mL. C: Silica at ﬁnal concentration of 1, 0.5, 0.25, 0.12
represents the mean of duplicate measurements.Boc-Leu-Lys-Arg-AMC and Cbz-Phe-Arg-AMC showed similar binding
afﬁnities with apparent KM values of 0.91 and 0.83 mM, respectively.
With the aim of obtaining a substrate with a low kcat and a high KM
[27], Boc-Leu-Lys-Arg-AMC was selected for further studies.
In BSA60 buffer, the kinetic constants of the substrate Boc-Leu-Lys-
Arg-AMC for other contact system related serine proteases in plasma
were investigated. In Table 2, these constants are compared with
those obtained for kallikrein. For FXIa, a KM of 3.4 mM and a kcat/KM of
8.2 · 103 M−1 s−1 were observed. For FXIIa andα-thrombin, KM values
of 0.92 mM and 0.74 mM, respectively, were found with a kcat/KM for
both enzymes of around 30 M−1 s−1. Plasmin showed KM and kcat/KM
values of 3.8 mM and 974 M−1 s−1, respectively.3.2. Calibrator
A western blot (Fig. 1) demonstrated assembly of α2M-kallikrein
complexes. A kallikrein related high molecular weight band was ob-
served in the lane containing a mixture of “crude α2M” and kallikrein
(lane 3). This band was not present in lanes including only kallikrein
(lane 1) or “crudeα2M” (lane 2). After gel ﬁltration, fractions containing
only the kallikrein related high-molecular weight protein were
obtained (lane 4).
In plasma, the initial amidolytic activity of α2M-kallikrein towards
the substrate, Boc-Leu-Lys-Arg-AMC, was constant for at least 1 h
(data not shown). The data conﬁrm that α2M-kallikrein complexesA®-PTT Automate 5, at ﬁnal dilution of 1:6, 1:12, 1:18, and 1:24. B: Dextran sulfate at ﬁnal
5 mg/mL, or no activator. Raw data (left) and ﬁrst derivative (right) are shown. Each line
1192 D. Biltoft et al. / Clinical Biochemistry 49 (2016) 1188–1194possess enzymatic activity towards small substrates that are protected
from other inhibitors in plasma.
In BSA60 buffer, the apparent KM of α2M-kallikrein towards
Boc-Leu-Lys-Arg-AMC was determined to 0.58 mM. This is somewhat
lower than the apparent KM of free kallikrein (0.91 mM).
3.3. Activating reagent
The potential of different activators to generate a measureable signal
in the current setup is shown in Fig. 2. The results demonstrate a low ac-
tivation potential of the APTT reagent (Fig. 2A). Both dextran sulfate
(Fig. 2B) and colloidal silica (Fig. 2C) were potent activators. However,
substantial turbidity of the sample followed the use of dextran sulfate in-
dicating precipitation of proteins in the mixture (data not shown). This
was not the case when silica was used as activator. No signal generation
was observed in the absence of activator (Fig. 2C, dashed black line).
3.4. Calculations
The recordedﬂuoresenceof the calibrator demonstrated a decreasing
reaction velocity at ﬁxed enzyme concentration (Fig. 3A, black line). TheFig. 3.Application of themathematical algorithms to correct for the effects from substrate deple
obtained from a generation experiment in a citrate pool with silica as activator (0.24 mg/mL, ﬁn
α2M-kallikrein as calibrator (33.3 nMkallikrein-like activity,ﬁnal concentration). A: The record
(dotted line), whichwas calculated from a 6th-degree polynomial ﬁt of the recorded ﬂuorescen
of the raw data from the generation sample (dotted line) and the “corrected” generation da
generation data before (dotted line) and after (black line) subtraction of α2M-kallikrein cont
the Thrombinoscope software (black dotted line).“correct” calibrator curve was determined (Fig. 3A, dotted line), and the
relation between the corrected and the observed calibrator curve was
found (Fig. 3B). Application of this relation to the raw generation data
(Fig. 3C, dotted line) resulted in a steady end-level signal (Fig. 3C, black
line). Measurements of substrate cleavage by α2M-kallikrein, formed
during the generation, were then substracted (Fig. 3D, black line). Final-
ly, the ﬂuorescence units were converted to enzyme concentration
(Fig. 3E, grey dotted line). This curve was identical to the curve obtained
when the calculations were performed by the Thrombinoscope software
(Fig. 3E, black dotted line).
3.5. Validation of kallikrein generation
Fluorescence developmentwas absent in plasmas depleted of FXII or
PK while signal generation was recorded in a citrate pool (Fig. 4A).
Addition of C1-inhibitor to a citrate pool diminished the ﬂuorescence
generated considerably compared to a citrate pool without added C1-
inhibitor (Fig. 4B). PK-32 also diminished the generation signal whereas
a very modest effect was seen when a nonsense antibody was added to
the plasma (Fig. 4B). Furthermore, the signal obtained declined with
decreasing levels of FXII (Fig. 4C). A substantially higher signaltion, the inner-ﬁlter effects, and cleavage of substrate byα2M-kallikrein. The rawdatawere
al concentration), Boc-Leu-Lys-Arg-AMC (0.42mM, ﬁnal concentration) as substrate, and
ed ﬂuorescence from the calibrator sample (black line) and the “corrected” calibrator curve
ce. B: Plot of the raw (measured) data versus the corrected calibrator data. C: First derivate
ta (black line), which was calculated using the relation observed in B. D: The corrected
ribution. E: The ﬁnal curve as obtained by manual calculations (grey dotted line) and by
Fig. 4. Validation of kallikrein generation. A: Signal generation in FXII depleted plasma (FXII DEP), prekallikrein depleted plasma (PK DEP), and a citrate pool is shown. B: Signal generation
in a citrate pool with addition of C1-inhibitor (80 μg/mL, ﬁnal concentration), PK-32 (15 μg/mL, ﬁnal concentration), nonsense antibody (15 μg/mL, ﬁnal concentration), or buffer alone is
presented. C: Signal generation in FXII-DEP, citrate pool aswell as FXII-DEPmixedwith 50%, 25%, 10%, and 0% citrate pool. D: Signal generation in EDTApool andHAE plasmas is shown. All
experimentswere done using silica as activator (0.24mg/mL,ﬁnal concentration),α2M-kallikrein as calibrator (33.3 nMkallikrein-like activity,ﬁnal concentration), and Boc-Leu-Lys-Arg-
AMC as substrate (0.42 mM, ﬁnal concentration). Calculations were carried out using the Thrombinoscope software.
1193D. Biltoft et al. / Clinical Biochemistry 49 (2016) 1188–1194generation was observed in plasmas with decreased C1-inhibitor
activity (HAE plasma) compared to the EDTA pool (Fig. 4D).
4. Discussion
In this article we present a series of experiments demonstrating a
possible setup for measuring FXII-dependent kallikrein generation in
undiluted plasma. The results obtained by the current method are
calibrated, thus the ﬁnal results represent generation of kallikrein
activity over time.
Michaelis-Menten kinetics of three ﬂuorogenic substrates for
kallikrein [26] were investigated to determine whether they were
suitable for continuous generation experiments, i.e. display high KM
and low kcat values [27]. As an effect of albumin on the hydrolysis of a
ﬂuorogenic substrate has been reported previously [28], the kinetic con-
stants were determined in bufferwith an albumin concentration similar
to that of plasma. Under these circumstances, Boc-Leu-Lys-Arg-AMC
displayed favorable kinetics for generation experiments with a high ap-
parent KM (0.91 mM) and a low kcat (19 s−1) with respect to kallikrein.
Cbz-Pro-Phe-Arg-AMC and Cbz-Phe-Arg-AMC showed KM values of 1.4
and 0.83 mM, respectively, and considerably higher kcat values (45 and
33 s−1, respectively). Furthermore, at low substrate concentrations, a
sigmoidal curvature of initial rate versus substrate concentration was
observed for both Cbz-Pro-Phe-Arg-AMC and Cbz-Phe-Arg-AMC (data
not shown). These observations are likely to be due to a strong interac-
tion between albumin and the substrates as, in the absence of albumin,
the relationship between initial rate and substrate concentration was
hyperbolic (Michaelis-Menten) for Cbz-Pro-Phe-Arg-AMC and Cbz-
Phe-Arg-AMC (data not shown). Because albumin is abundant in
plasma, the use of Cbz-Pro-Phe-Arg-AMC or Cbz-Phe-Arg-AMC may be
accompanied by signiﬁcant complications in the current setup.
The selectivity of Boc-Leu-Lys-Arg-AMC for plasma kallikrein com-
pared to other serine proteases is of major importance. The selectivity
of the substrate was investigated by comparing the kinetic constants
for kallikrein, FXIIa, FXIa, thrombin, andplasmin (Table 2). The substrate
demonstrated higher KM for FXIa and plasmin than for kallikrein but
comparable or lower KM for FXIIa and thrombin. However, very lowkcat/KM values were observed for both FXIIa and thrombin compared
to kallikrein, and a signiﬁcant contribution from these enzymes upon
signal generation is therefore unlikely. In addition, many of the prote-
ases are present in plasma in much lower concentrations than that of
prekallikrein. For example, the plasma concentration of FXI is around
twenty times lower than that of prekallikrein [16]. Even though a
two-fold difference between the kcat/KM for kallikrein and FXIa was re-
corded, the signal development from cleavage by FXIa will be minimal
[21]. Furthermore, the initial phase of contact activation does not
require presence of calcium. Consequently, re-calciﬁcation is omitted
securing no or very little activation of calcium dependent proteases.
The enzymatic capacity of the α2M-thrombin complex, used as
calibrator in the CAT-method [18], is not affected by inhibitors
in plasma but retains the ability to cleave small substrates.
α2M-kallikrein was likewise unaffected by inhibitors in plasma as
no decrease in activity was observed after incubation in plasma for
1 h. It is preferable that the afﬁnity of the substrate for kallikrein
and α2M-kallikrein is similar for calibration. However, complex for-
mation between kallikrein andα2M affected the kinetic constant KM,
which appeared lower towards the substrate when kallikrein was
bound to α2M. It is peculiar that interaction between the enzyme
and an inhibitor result in an apparently improved binding afﬁnity
(i.e. lower KM) of the substrate. However, this ﬁnding is in
accordance with previous reports, in which a similar trend was
observed for human α2M-kallikrein [29], α2M-trypsin [30], and
α2M-thrombin [31] complexes. The effect of difference in KM upon
calibration was not investigated here.
Polyphosphates [32] and misfolded proteins [33] have been pro-
posed as physiological activators of the contact system, but the subject
is still under study. Other assays relying on contact activation, such as
the APTT and contact dependent thrombin generation, employ non-
physiological activators. In light of this, we investigated several of the
known non-physiological activators in the current setup. When the
APTT reagent was used as activator, a moderate signal was observed.
The signal diminished dose-dependently with lower concentration
of APTT reagent. At high concentrations, both dextran sulfate and
colloidal silica generated a stronger signal than the APTT reagent. The
1194 D. Biltoft et al. / Clinical Biochemistry 49 (2016) 1188–1194use of dextran sulfate, however, resulted in signiﬁcant turbidity, which
presumably is caused by dextran sulfate induced precipitation of
proteins. This was not observed when silica was used as the activator.
Variation in pre-analytical handling of samples can affect test consis-
tency [34,35]. While the effects of pre-analytical factors were not inves-
tigated in the present study, we did not record any signal development
in the absence of contact activator. These ﬁndings indicate that the
proposed method is not affected by the surface of the microtiter plate.
Furthermore, the ﬁndings also indicate that the reported activity of
PK-HMWK complexes [36] is not detected by the current method.
The current analytical setup does, however, suffer from other obsta-
cles seen in the CAT-method including effects of substrate depletion,
the inner-ﬁlter effect, and cleavage of substrate by the formation of
α2M-enzyme complexes. In the CAT-method, mathematical algorithms
are used to circumvent these obstacles and such algorithms should
be applicable in the current setup as well. The manual calculations
presented here showed that the algorithms could be used to overcome
these complications.
The validation experiments strongly indicated that the observed
signal was related to FXII-driven kallikrein generation. We observed
no signal in plasmas depleted of FXII or PK conﬁrming that the presence
of these proteins is required. Furthermore, adding citrate pool to the FXII
DEP dose-dependently restored signal generation. This indicates a con-
siderable effect from plasma levels of FXII. The amount of C1-inhibitor
activity in plasma also affected the signal generated substantially. Addi-
tion of C1-inhibitor to a citrate pool diminished signal generation,
whereas plasmas with decreased C1-inhibitor activity (HAE plasma)
generated a much stronger signal. These ﬁndings, in combination with
the selectivity studies of the substrate, strongly suggest that the pro-
posed method predominantly measures kallikrein activity over time.
In the present series of experiments, we have demonstrated that
calibrated kallikrein generation can be determined in undiluted
human plasma samples. Our experiments could lay down the basis
of a functional, sensitive, and accurate global assay for measurements
of the initial activation phase of the contact system. Furthermore,
the experiments show that such a method could be useful to study
abnormalities in the contact activation system as the signal was
considerably affected by levels of FXII, PK, and C1-inhibitor.
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